A new article on BC007 appeared in Atlas of Science.
https://atlasofscience.org/the-aptamer-bc007-for-the-treatment-of-functional-autoantibody-diseases-first-developed-for-patients-with-dilated-cardiomyopathy/
Read More
Berlin Cures Set to Launch Phase 2 Study of Heart Failure Drug
Berlin Cures Set to Launch Phase 2 Study of Heart Failure Drug
BC007 Neutralizes Autoantibodies That Cause 80% of Dilated Cardiomyopathy
ZUG, Switzerland, and BERLIN, Germany, January 7, 2018 – A drug designed to neutralize autoantibodies linked to heart failure is set to begin Phase 2 testing early in 2018, the drug’s developer, Berlin Cures, said today.
The double-blind study will eva...
Read More
New Paper: Performance and in-house validation of a bioassay for the determination of beta1-autoantibodies found in patients with cardiomyopathy (open access)
http://authors.elsevier.com/sd/article/S2405844016324392
Read More
AUTOIMMUNITY REVIEWS 2017: Cardiomyopathy — An approach to the autoimmune background
European J of Pharmacology: Aptamer BC 007 – A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors
Circulation 2000, eliminating Beta1-autoantibodies in heartfailure patients
The positive effects of elimination of Beta1-autoantibodies was first described in 2000
Fulltext can be downloaded here
Circulation-2000-Müller-385-91
Read More
Circulation Research 2011;109: Aptamer Neutralization of Beta1-Adrenoceptor Autoantibodies Isolated From Patients With Cardiomyopathies (free full-text)
The aptamer can eliminate Beta1-Adrenoceptor Autoantibodies
Download free full text pdf:
Circulation Research-2011;109:986-992
Read More